In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology (VHL/HIF/VEGF/EGFr).

You cannot participate in this study if any of the following apply to you:

Age < 18 years

Treatment with more than one previous regimen for metastatic disease

Clinically significant cardiovascular disease

Active brain metastases

History of CNS disease

Clinical history of coughing or vomiting blood.

History of thromboembolic disease.

PEG or G-tube are ineligible.

Current use of full dose anticoagulants or thrombolytic agents

Chronic daily treatment with aspirin or NSAIDS

Any clinical evidence or history of a bleeding or clotting disorder

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00193154